Loading
Iqvia Holdings Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 07 Feb 2025.
Iqvia Holdings Inc.: what insiders have been doing
Iqvia Holdings Inc., classified in the Healthcare & Pharma sector, is a listed company based in Danbury, United States, founded in 2016. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Iqvia Holdings Inc. logged 39 filings by 19 insiders.
All open-market trades in the period are sales: 9 sales worth €26.2M, by 6 insiders, with no purchase on record. At €11.4M, the sale published on 31 July 2026 by Bousbib Ari is the largest of the period (0.030% of market cap).
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,816 companies, median 19 filings), a count of 39 filings is above the norm. The full history, which starts in 2021, counts 3 purchases against 20 sales. The 10-K for the year ended 31 December 2025 shows 16.31 bn USD of revenue and 1.36 bn USD of net income.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
134
Thresholds
n/a
Buy Volume
€247,135
3 ops. · all time
Sell Volume
€165M
20 ops. · all time
Who traded when
BuySaleAri Bousbib4 sales
Keriann Cherofsky2 sales
Bhavik Patel1 sale
Eric Sherbet1 sale
James G. Berkshire1 sale
John G. Danhakl1 buy
+1 other insider
Since the insiders bought
- -6.9%Entry US$206.97 · Close at T+365 US$192.67
- -6.7%Entry US$228.27 · Close at T+365 US$212.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Iqvia Holdings Inc. Strong Buy (bullish), based on 19 analysts. Average price target: US$295.05.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,385 of 24,148 companies
53.0
score / 100
Value49
Quality57
FCF yld4.7%
Earn yld3.1%
EV/EBITDA16.8x
ROE23%
Gross mgn33%
Net mgn8.3%
Debt/EBITDA4.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$260.68
Analyst consensus
19 analystsStrong buy
US$250.00Target US$295.05(+13%)US$345.00
Income statement
RevenueUS$16.3B
Gross profitUS$5.4B33% margin
EBITDAUS$3.5B21% margin
Net incomeUS$1.4B8.1% margin
Valuation
PER (trailing)32.4x
PER (forward)18.1x
P/Book7.0x
Beta1.17
Balance sheet & cash
Market capUS$42.9B
Total debtUS$14.2B
Free Cash FlowUS$2.1B
Debt / Equity258%
Profitability & ownership
ROE22.8%
ROA5.1%
% insiders1.1%
% institutions103.6%
Last declaration on 4 September 2026
Declarations134 total
5,381 shares@ US$131.820.0016% mcap33.5% of flowCommon StockSEC:0001628280-26-060755:0
2,713 shares@ US$261.540.0016% mcap33.5% of flowCommon StockSEC:0001628280-26-060755:2
2,668 shares@ US$261.330.0016% mcap32.9% of flowCommon StockSEC:0001628280-26-060755:1
1,855 shares@ US$235.270.0010% mcap87.5% of flowCommon StockSEC:0001628280-26-052701:0
5,500 shares@ US$232.680.0029% mcap34.1% of flowCommon StockSEC:0001628280-26-052703:0
5,500 shares@ US$232.680.0029% mcap100.0% of flowCommonSEC144:0001950047-26-007499
1,855 shares@ US$235.26990.0010% mcap100.0% of flowCommonSEC144:0001950047-26-007452
4,584 shares@ US$246.850.0026% mcap1.7% of flowCommon StockSEC:0001628280-26-051449:2
156,206 shares@ US$78.210.028% mcap18.6% of flowCommon StockSEC:0001628280-26-051449:0
4,465 shares@ US$247.100.0025% mcap1.7% of flowCommon StockSEC:0001628280-26-051449:1
44,039 shares@ US$246.080.025% mcap16.5% of flowCommon StockSEC:0001628280-26-051449:3
53,191 shares@ US$244.780.030% mcap19.8% of flowCommon StockSEC:0001628280-26-051449:4
47,858 shares@ US$244.600.027% mcap17.8% of flowCommon StockSEC:0001628280-26-051449:5
2,069 shares@ US$247.000.0012% mcap0.8% of flowCommon StockSEC:0001628280-26-051449:6
558 shares@ US$245.210.0003% mcap46.4% of flowCommon StockSEC:0001628280-26-051450:0
5,000 shares@ US$249.160.0028% mcap26.7% of flowCommon StockSEC:0001628280-26-051451:0
106,279 shares@ US$245.50380.059% mcap100.0% of flowCommonSEC144:0001950047-26-007379
558 shares@ US$245.210.0003% mcap100.0% of flowCommonSEC144:0001950047-26-007386
5,000 shares@ US$249.1550.0028% mcap100.0% of flowCommonSEC144:0001950047-26-007383
1,571 shares0Common StockSEC:0001628280-26-027607:0
1,571 shares0Common StockSEC:0001628280-26-027609:0
1,571 shares0Common StockSEC:0001628280-26-027596:0
1,571 shares0Common StockSEC:0001628280-26-027604:0
20 shares@ US$166.94100.0% of flowCommon StockSEC:0001628280-26-008661:0
123 shares@ US$166.9415.6% of flowCommon StockSEC:0001628280-26-008659:0
25 of 134 declarations
About Iqvia Holdings Inc.
IQVIA Holdings Inc. (NYSE: IQV) is a leading global player in life sciences and healthcare services, operating at the intersection of data, technology and clinical research. The company is headquartered in Durham, North Carolina, United States, and maintains a broad global footprint across more than 100 countries with approximately 93,000 employees. IQVIA was created in 2016 through the merger of Quintiles and IMS Health, and the combined company adopted the IQVIA brand in 2017. ([iqvia.com](https://www.iqvia.com/about-us))
IQVIA’s business model is now built around two core operating pillars. On the R&D side, the company provides clinical trial services, patient and site solutions, central laboratory services, functional outsourcing and R&D consulting. On the commercial side, IQVIA offers analytics, market intelligence, commercial engagement services, patient support and decision-support tools for pharma and other healthcare clients. Its IQVIA Connected Intelligence platform and healthcare-grade AI capabilities are central to its value proposition, linking healthcare data, technology and domain expertise. ([iqvia.com](https://www.iqvia.com/about-us))
Read moreShow less
From a competitive standpoint, IQVIA stands out because it combines one of the industry’s deepest data assets with global clinical execution capabilities and increasingly sophisticated software and analytics offerings. That makes it a strategic partner for large pharmaceutical companies, biotech firms, medtech players, payers and certain public-sector organizations. The company also benefits from broad therapeutic coverage, spanning oncology, rare diseases, cardiovascular care, vaccines, central nervous system disorders and endocrinology. ([iqvia.com](https://www.iqvia.com/about-us))
IQVIA’s international presence is a key advantage in an industry where multinational trials, complex regulation and real-world evidence generation require cross-border scale. The company’s services are used across clinical development, commercialization, safety and healthcare intelligence workflows, giving it a diversified exposure across the biopharma value chain. ([iqvia.com](https://www.iqvia.com/about-us))
Recent developments reinforce that strategic positioning. In May 2026, IQVIA reported strong first-quarter 2026 results, with growth in both major segments, and reaffirmed its full-year 2026 guidance. Earlier in 2026, the company also simplified its internal operating model, announced a strategic commercial data collaboration, and signed an agreement to acquire drug-discovery assets from Charles River Laboratories to expand its end-to-end discovery capabilities. Collectively, these moves point to a business increasingly focused on AI, operating efficiency and extending its reach further upstream and downstream in the pharmaceutical value chain. ([ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Reports-First-Quarter-2026-Results/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
